Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Latest shares articles
Trading the Nasdaq 100 as Tariffs Take Effect
Not far off recovering from last Thursday’s losses buoyed by big gains from a few of Big Tech, and in sentiment still a story of majority buy bias.
06:35, 7 August 2025
Capital.com donates €50,000 to the Cyprus Red Cross Society to support wildfire relief efforts
Capital.com donates €50,000 to the Cyprus Red Cross Society to aid families affected by wildfires, reinforcing its commitment to community support.
09:49, 5 August 2025
Trading the Dow 30 after the disappointing Non-Farm Payrolls
Technical overview shifts in the key index following the pullback late last week made worse by a deteriorating labor market, while CoT speculators shift to net sell for the first time in months.
07:55, 4 August 2025
Forex CFDs: Understanding currency forwards vs spot markets
Spot or forward? These two forex markets behave differently, and now you can trade both with us as forex CFDs. Here’s how they work, and what sets them apart.
14:48, 31 July 2025
Ratings and Reviews
Ratings and Reviews
